Global Position Statement on testosterone treatment for women

The first Global Position Statement on the use of testosterone in the treatment of women, led by the International Menopause Society (IMS), was published in four leading international medical journals on 2 September 2019: Climacteric, Maturitas, The Journal of Sexual Medicine, and The Journal of Clinical Endocrinology and Metabolism. The statement has been authored by a diverse team of leading experts…

#EMAS2019 in the news

#EMAS2019 in the news Integrating novel scientific insights into clinical application the multidisciplinary international congress was extremely successful and enjoyed by all participants. As part of its menopause week, the BBC filmed speakers on both women’s and men’s health. The clips are below. We look forward to May 2021 when the next congress will be in…

Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Collaborative Group on Hormonal Factors in Breast Cancer

30 August 2019 A meta-analysis covering the period January 1992 to January 2018 has been published in the Lancet by the Collaborative Group on Hormonal Factors in Breast Cancer. It has reported on the risk of breast cancer with MHT in relation to the type and timing of therapy. During prospective follow-up, 108 647 postmenopausal women…

On the use and abuse of register studies: the case of menopausal hormone therapy

The EMAS officers have commented on the recent manuscript by Savolainen-Peltonen et al., published on the British Medical Journal in an open access editorial published in Maturitas. This Finnish registry study explored the association between the use of MHT in post-menopausal women and a diagnosis of Alzheimer’s disease (AD). The main finding was that women…

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

Amsterdam, June 06, 2017 – A new position statement by the European Menopause and Andropause Society(EMAS) published in the journal Maturitas summarises the evidence about drug holidays from bisphosphonates and denosumab in women with postmenopausal osteoporosis. Osteoporosis affects 1 in 3 women. Bisphosphonates, such as alendronate, risendronate and zoledronic acid, and denosumab are used extensively…